Our first review on progress and prospects in cystic fibrosis (CF) gene therapy was published in this series in October 2002. We now summarize the progress made since then and comment on the prospects for CF gene therapy over the next couple of years. Three clinical trials have been carried out, further supporting the proof-of-principle that gene transfer to the airway epithelium is feasible. Developments in viral and non-viral vectors, as well as recent alternative strategies such as gene repair, trans-splicing and stem cell therapy will be reviewed.
The use of adeno-associated virus has steadily increased in the last few years, but repeat administration remains an unresolved problem Adeno-associated virus (AAV) serotype 2 was the first AAV-based vector assessed for lung transduction, as well as transduction of other tissues and has progressed into clinical cystic fibrosis (CF) gene therapy trials (see below). More recently, AAV2 with capsids from serotypes 1, 5 and 6 have been evaluated for lung gene therapy and appear to be more efficient in transducing airway epithelial cells than AAV2. 1, 2 To search for potent AAV vectors with enhanced performance profiles, molecular techniques were employed for the detection and isolation of endogenous AAVs from a variety of human and non-human primate (NHP) tissues. 3 Ten novel virus sequences were identified, but it remains to be established whether these viruses are suitable for gene therapy applications.
The use of adeno-associated virus (AAV) has steadily increased in the last few years, but repeat administration remains an unresolved problem. Two out of the three clinical trials published in the period covered by this review used AAV2 vectors. The use of adenoviral vectors has decreased in the last 3 years. Inefficient repeat administration hinders progression of recombinant Sendai virus into clinical trials. Targeting of resident lung stem or progenitor cells with integrating lentiviral vectors is showing promise. The development of new non-viral formulations has been moderately successful. One non-viral trial has been published in the period covered by this review. Inefficiency, and concerns about accuracy, limit the success of gene repair and trans-splicing technologies. The relevance of fetal gene therapy and circulating bone marrow stem cell therapy to cystic fibrosis is unclear.
Prospects
The first non-viral repeat dose (monthly administration over 6 months) lung trial will be carried out looking at changes in clinically relevant surrogate end points of lung function. The addition of physical energy (magnetofection and sonoporation) continues to be evaluated for lung gene transfer. Novel plasmid designs (CpG depletion, long-lasting promoters, codon optimization) will progress into clinical studies. The understanding on how plasmid DNA is taken up by primary airway epithelial cells and movement through the cytoplasm and into the nucleus will be further studied. The role of circulating stem cells in lung repopulation, as well as the identification of resident stem cells will be further followed.
It has previously been reported that tripeptidyl aldehyde-based proteasome inhibitors increase AAV2 and AAV5 transduction in vitro. In a more recent study, Yan et al. 4 reported that anthracycline-based proteasome inhibitors such as doxorubicin have a similar, albeit celltype-specific effect. Interestingly, in certain cell types, the effect of tripeptidyl aldehyde-and anthracycline-based inhibitors was additive, arguing for modulation of different proteasome functions or an additive effect on the same pathway.
The feasibility of repeated AAV administration is still unresolved. Although the unsuccessful AAV2 repeat administration trial (see below) and pre-2003 studies may argue for problems with repeat administration, Fischer et al. 5 more recently reported successful re-administration of AAV2 (three doses) into rhesus macaques. However, although some low level of green fluorescent protein (GFP) reporter gene expression was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and via immunohistochemistry, it is unclear how expression levels compared to onetime administration levels. Importantly, repeated AAV2 administration caused an increase in AAV2-neutralizing antibodies, but did not induce lung inflammation. Finally, Halbert et al. 6 showed efficient and persistent (18 months) AAV6-mediated reporter gene expression in a rat model. Although currently unpublished, the authors claimed that repeated administration after 18 months resulted in significant gene expression (50% of first dose levels in three rats). A nose trial has been planned and it has been proposed to use an easy to assay marker gene, rather than a therapeutic gene (C Halbert, North American CF Conference, 2005). Although the data are interesting, the limited capacity of AAV to carry the full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene and a suitably strong promoter remains a significant problem. However, Lai et al. 7 have recently shown that the efficiency of AAV trans-splicing can be greatly improved through rational vector design and may, therefore, allow the CFTR cDNA to be split between two viral vectors.
Two out of the three clinical trials published in the period covered by this review used AAV2 vectors
The study by Flotte et al. 8 discussed here was originally undertaken as the first human AAV trial, but publication was superseded by phase I and phase I/II trials administering AAV2 to the maxillary sinus and whole lung, respectively. These studies fall outside the time frame of this review, but have previously been discussed. In the present study, AAV2 was administered to the nasal epithelium and to a segment of the right lung of 25 CF patients with mild to moderate lung disease during bronchoscopy. The study was primarily designed to assess safety, as well as viral shedding, over a wide dose range (up to 2 Â 10 12 DNase-resistant particles). Although results for virus shedding were inconclusive for 16 out of the 25 patients owing to technical problems, shedding was detected in only one of the nine remaining patients. Importantly, anti-AAV-neutralizing antibodies increased in patients receiving high viral doses, which may interfere with re-administration of AAV2 in man. As expected, adverse effects were frequently noted in this patient cohort, but only one was thought to have been linked to virus administration. Gene transfer was assessed indirectly by measuring AAV-DNA, appeared dose-dependent, but was generally low (o0.05 vector copies/cell). Vector-specific mRNA was not assessed, owing to the inefficient DNA detection. Interestingly, based on the detection of vector-specific DNA, transfection efficiency of the nasal epithelium appeared less efficient than for bronchial epithelium. The authors speculated that arginine-glycine-aspartate-integrins, which are AAV2 co-receptors, might be less abundant in the nose compared to bronchial epithelium. There was no change in nasal potential difference measurements, a readout of CFTR function, after AAV2 transduction.
The detection of AAV-specific mRNA has been challenging in pre-clinical and clinical studies. In particular, the presence of single-stranded AAV genomes can interfere with RT-PCR assays. Gerard et al. 9 have overcome this problem, by developing a method that allows specific cDNA synthesis and subsequent PCR amplification from mRNA templates (RNA-specific RT-PCR). In an attempt to address this problem further, Flotte et al. 10 studied primary nasal epithelial cells obtained from patients in the trial described above. At different time points after gene transfer, nasal cells were collected and expanded in vitro, with the aim of correlating AAV-DNA detection with CFTR mRNA expression and function. In three out of five subjects, vector-specific mRNA was detectable; in two out of these, there was also evidence of an increase in chloride transport. There are several caveats to the interpretation of these data including low n numbers, the potential for delayed uptake of AAV into the cell nucleus during cell division ex vivo, thereby producing false positives and enhanced strand synthesis or transcription ex vivo. However, the authors suggest a correlation between vector-specific CFTR DNA, mRNA and function in these patients, detectable only after ex vivo cell expansion.
Moss et al. 11 published a phase II trial assessing the safety and efficacy of repeated administration (three doses 1 month apart, 10
13 DNase-resistant particles/dose) of AAV2. Similar to the study by Flotte et al., viral shedding and increases in neutralizing antibodies were noted, but virus administration was safe. Importantly, a significant reduction in sputum interleukin 8 (a proinflammatory cytokine) and an improvement in lung function (forced expiratory volume (FEV 1 )) was seen after the first administration, but not after the second or third administration. On the basis of these studies, Targeted Genetics Corporation initiated a large repeat-administration study (100 subjects), sufficiently powered to detect significant changes in lung function. However, recently the company announced that the trial had not met its primary outcome measure and, therefore, the CF program had been discontinued. There maybe several reasons for these disappointing results: (1) AAV2 is too inefficient in transducing airway epithelial cells via the apical membrane, (2) the ITR promoter used to drive CFTR expression is too weak and (3) repeat administration of AAV2 to the lung is not possible owing to the development of an anti-viral immune response.
Finally, on the back of previously published AAV2 aerosolization studies, Croteau et al. 12 evaluated the Gene therapy progress and prospects: cystic fibrosis U Griesenbach et al effects of exposure of health-care workers to AAV2. Based on airborne vector particle calculations, the authors estimated exposure to 0.0006% of the administered dose. At this dose, no deleterious health effects were detected.
Use of adenoviral vectors has decreased in the last 3 years
Although frequently used in the early days of CF gene therapy, more recently the use of adenoviral vectors has decreased. This is not only owing to low-transduction efficiency in human airway epithelial cells but also the inability for re-administration. However, two pre-clinical studies have recently addressed whether adenovirusmediated CFTR expression ameliorated bacteria-induced inflammation in the lungs of CF knockout mice. Koehler et al. 13 demonstrated that transduction with helperdependent Ad-CFTR ameliorated Burkholderia cepaciainduced lung inflammation, as well as bacterial load, in CF mice. Along similar lines, van Heeckeren et al.
14 assessed if Pseudomonas aeruginosa-induced inflammation/infection was altered after Ad-CFTR transduction. Interestingly, mice infected with either Ad-CFTR or an Ad-control virus showed improved survival compared to diluent-treated mice, which may in part have been owing to protective adenovirus-induced proinflammatory responses. The above studies indicate that adenovirus-mediated CFTR expression may, to a degree, protect CF mice from the effects of bacteria-induced lung inflammation.
Hiatt et al. 15 have recently shown that the addition of lysophosphatidylcholine (LPC) improves the transduction efficiency of helper-dependent adenovirus in NHP lung. LPC opens tight junctions and allows the virus to reach the CAR receptor at the basolateral membrane.
A study by Tosi et al. 16 raised concerns that antiadenovirus immune responses (cytotoxic T-lymphocyte responses and major histocompatibility complex class I antigen presentation) may be further enhanced if the host has a pre-existing Pseudomonas infection. These data further highlight potential problems for adenoviral vectors in CF gene therapy and the use of adenoviral vectors for CF gene therapy is likely to be restricted to pre-clinical proof-of-principle studies, until the problems of repeat administration can be overcome.
Inefficient repeat administration hinders progression of recombinant Sendai virus into clinical trials
We have previously shown that recombinant Sendai virus (SeV) is a very efficient gene transfer agent for airway epithelial cells. The original studies were carried out using a first-generation transmission-competent virus. More recently, Ferrari et al. 17 showed that potentially safer, second-generation transmission-incompetent SeVs maintain this high transfection efficiency (Figure 1) . Importantly, we also showed that transmission-incompetent SeV-CFTR can correct the chloride transport defect in CF knockout mice. 18 However, SeV-mediated expression is transient and, therefore, requires repeat administration. However, this is inefficient and attempts at tolerization against immuno-dominant SeV peptides were unsuccessful. 19, 20 Although SeV may be useful for acute diseases that require only transient gene expression, in the context of CF, the use of SeV will be, as for adenovirus, restricted to pre-clinical proof-of-principle studies, until repeat administration problems can be solved.
Targeting of resident lung stem or progenitor cells with integrating lentiviral vectors is showing promise
Several groups, including our own, have attempted to generate lentiviral vectors for persistent gene expression in airway epithelium. Jim Wilson's group has previously reported that human immunodeficiency virus, pseudotyped with Ebola virus envelope glycoproteins, transduces airway epithelium via the apical membrane. A more recent study extended this work, by further defining the minimal protein domains of Ebola virus sufficient for airway transduction. 21 In his most recent study, Sinn et al. 22 compared feline immunodeficiency virus (FIV), pseudotyped with a variety of envelope proteins including the baculovirus GP64 envelope glycoprotein, reporting high titre production and persistent expression in the mouse nose (50 weeks). Both the respiratory and the olfactory epithelium were transduced, and interestingly, transduction efficiency was enhanced when the virus was mixed with methylcellulose (MC). The authors had previously reported that MC increased airway epithelial cell transduction of a variety of viruses, including FIV, AAV and adenovirus, probably by decreasing mucociliary clearance.
A simian immunodeficiency virus pseudotyped with the SeV membrane proteins F (fusion protein) and HN (hemagluttinin-neuraminidase), which are responsible for efficient uptake of SeV into airway epithelial cells, has been developed. 23 Following perfusion into the nasal epithelium, F/HN-SIV efficiently and persistently (200 days) transduced respiratory epithelial cells (the target for CF gene therapy).
It is currently unknown which cell types have been transduced in these studies. Further, it is not clear whether persistent expression is owing to stem/progeni- Gene therapy progress and prospects: cystic fibrosis U Griesenbach et al tor cell integration or the ability of surface epithelial cells to divide slowly. Studies are currently underway to assess the feasibility of repeated administration of lentiviral vectors into airways in several groups, including our own, and further data are needed before the relevance of lentiviruses for CF gene therapy can be decided. In addition, the safety profile of virus insertion into the genome of airway epithelial cells has to be carefully monitored.
Development of new non-viral formulations has been moderately successful
Although novel non-viral formulations are constantly being developed, [24] [25] [26] [27] [28] careful side-by-side comparison with existing 'gold standard' non-viral formulations in relevant in vivo models is generally missing. In an attempt to address this, the UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk) has set up a mouse core facility to compare existing non-viral formulations by actively recruiting formulations from academic and industrial partners. After applying stringent selection criteria to allow for rapid translation into a clinical trial (Table 1) , three previously described nonviral gene transfer agents (polyethylenimine (PEI 25 kD, Sigma-Aldrich, Gillingham, Dorset, UK), cationic lipid 67 (GL67, Genzyme Corporation, Framingham, MA, USA) and DNA nanoparticles (Copernicus Therapeutics, Cleveland, OH, USA)) were compared head-to-head in the CF mouse nose 29 and after nebulization in sheep lung. 30 Detection of vector-specific human CFTR mRNA was the most robust end point. Based on the milder phenotype in CF patients with low-level residual CFTR function, it is generally anticipated that expression of approximately 5% of endogenous levels may be sufficient to ameliorate CF lung disease. It is worth noting that sheep transfected with a human CFTR plasmid, complexed with GL67, produced at least equal amounts of human CFTR in airway epithelial cells when compared to endogenous ovine CFTR mRNA. On the back of these data, a clinical trial programme has started.
The addition of physical energy is an interesting approach to increase non-viral gene transfer. Although successful in mice, 31 the translation of lung electroporation into large animal models (sheep) has been difficult, because the design of equipment that would allow exposure of large regions of the sheep lung to electrical current has been problematic (I Pringle, personal communication). In our first review in this series, we mentioned the potential of magnetic force to increase gene transfer to the airway epithelium. 32 This strategy continues to be developed. In particular, oscillating magnets may help to 'pull' magnetic DNA through CF sputum (J Dobson, personal communication). In addition, lung sonoporation (ultrasound-mediated gene transfer) is starting to look interesting. 33 It is currently uncertain how the inflammatory milieu in the CF lung will affect transfection efficiency. Bastonero et al. 34 reported that the inflammatory cytokines tumor necrosis factor-a and interleukin-4 inhibited cationic-lipid-mediated gene transfer in a CF cell line, but it is unclear if this is a cell line-specific phenomenon or occurs in vivo as well.
Recently, Kim et al. 35 reported that proteasome inhibitors, which successfully increase AAV transduction, may also enhance peptide-mediated non-viral gene delivery systems. However, these adjuncts still have to be carefully assessed in relevant in vivo models.
In summary, although the development of novel nonviral formulations has been slow, the assessment of the most efficient currently available formulation in a carefully designed repeat-dose clinical trial will address whether the efficiency of non-viral gene transfer is sufficient to translate into clinical benefit in the CF lung. In addition, a variety of strategies are assessed to further improve efficiency of existing formulations.
One non-viral trial has been published in the period covered by this review
The only non-viral trial during the period covered by this review assessed compacted nanoparticle-mediated gene transfer into the nasal epithelium. 36 Plasmid DNA carrying the CFTR cDNA under the control of a CMV promoter/enhancer was compacted with polyethylene glycol-substituted 30-mer polylysine and was slowly perfused onto the nasal epithelium. The study was mainly designed as a phase I dose-escalation safety study (12 subjects), but efficacy end points were also assessed. Although initially planned as a within-subject placebo-controlled study, administration of the active compound into one nostril led to cross-contamination on the contralateral side, and thus placebo controls were not possible. No side effects of administration of DNA nanoparticles to the nasal epithelium were noted. Vectorspecific mRNA could not be detected, but chloride transport was increased in eight out of 12 patients when compared to pre-treatment values, although some aspects of the protocol used for nasal potential difference measurements may have been suboptimal (perfusion times for the amiloride and low chloride solutions).
It has previously been suggested that the small size of DNA nanoparticles (20 nm) may be responsible for efficient gene transfer into non-dividing airway epithelial cells. In addition, it has recently been reported that uptake of nanoparticles is mediated by nucleolin, which is expressed on the apical membrane of airway epithelial cells, and which shuttles cargo directly into the nucleus (P Davis, personal communication). A follow-on study looking at single-dose aerosolization of DNA nanoparticles into CF lungs is currently planned.
In summary, some of the above clinical studies further support the concept of CF gene therapy. In our view, the design of future trials should consider some or more of the following: (a) the need to demonstrate feasibility of repeated administration of a gene transfer agent, Although proof-of-principle for AAV-based splicosome-mediated trans-splicing in cell lines looks encouraging, 38 replication of the technology in lung in vivo has not been published yet. Low-transduction efficiency may in part be responsible. Although end point assays are suitable to quantify 'correct' trans-splicing events, it is currently unclear how much 'inappropriate' gene repair and trans-splicing occurs, mainly because assays are insufficient to address these questions. Thus, in the short term, it is unlikely these strategies will lead to clinical trials.
Relevance of fetal gene therapy and circulating bone marrow stem cell therapy to CF is unclear , it is currently difficult to see a clear clinical application. Unless the hypothesis that the absence of CFTR in utero causes significant and irreparable developmental defects proves correct, in utero gene transfer, particularly using integrating long-lasting vectors, will most likely be considered too risky, given the pre-requisite for in utero screening and hence alternative strategies.
The proposed role for CFTR during in utero development is continued to be discussed. Cohen and Larson 40 transiently shut-down CFTR expression in rat fetuses with antisense CFTR and reported the development of CF-like pathological changes including lung fibrosis and inflammation.
Ex vivo transduction of bone marrow-derived stem cells (BMSCs) with integrating retro-and lentiviral vectors is a well-established, efficient technique. In combination with the concept that bone marrow-derived hematopoietic or mesenchymal stem cells may have the capacity to differentitate into airway epithelial cells, 41 some groups have speculated that this strategy may have applications for the treatment of CF. Using slightly different models, both groups suggested that BMSCs were able to adopt properties of alveolar and respiratory epithelium. The frequency of trans-differentiation appeared to be higher in alveolar than in respiratory epithelium and seemed to be enhanced, when the airway epithelium was damaged. However, subsequent to these papers intensive discussion and further studies have questioned these data. Importantly, Kotton et al. 42 was unable to reproduce their original findings in a follow-up study using a different technique to identify bone marrow-derived pneumocytes. This highlights the significant technical problem associated with conclusive identification of bone marrowderived alveolar and airway epithelial cells. However, after careful optimization of the detection techniques, Macpherson et al. 43 maintain that approximately 1% of tracheal epithelial cells are bone marrow-derived following detergent damage.
In our view, ex vivo transduction and systemic re-administration of BMSCs does currently not hold great promise for CF for a number of reasons: (a) data on trans-differentiation in the lung is conflicting, (b) both myeloablation and extensive damage of the lung appear to be pre-requisites for engraftment, neither of which are likely to be clinically applicable and (c) in reports that provided evidence of engraftment and differentiation, the frequency in conducting airways is very low (o1%).
Prospects
In the next few years, a number of important questions will be addressed. The UK CF Gene Therapy Consortium clinical trial programme will assess whether the most efficient currently available non-viral gene transfer agent is able to alter CF lung disease. Physical delivery methods such as ultrasound and magnetofection have shown promising results in vitro and in small animal models. Translation into larger animal models is challenging, but will be attempted. In our 2002 review, we predicted further development of epithelial cell-specific regulated expression cassettes, but no significant advances have been made. In contrast, the understanding of the importance of CpG islands within plasmid DNA in inducing lung inflammation and their effects on duration of gene expression has moved forward rapidly and will affect the design of plasmids for future trials. 44 The understanding of how plasmid DNA is taken up by primary airway epithelial cells, its movement through the cytoplasm and subsequently into the nucleus will be further studied. Although the interest in new animal models for CF remains high, no significant progress has been made since the last review. In the next few years, the question of whether circulating stem cells can contribute to lung repair will be further addressed and a better understanding of resident stem cells within the lung is likely to be achieved.
Conclusions
New developments in the design of viral and non-viral vectors for airway gene transfer are constantly being Gene therapy progress and prospects: cystic fibrosis U Griesenbach et al made. The key question in the context of viral vectors is that of repeat administration, which is an absolute requirement for a chronic life-long disease such as CF, unless a 'single-hit' transduction of resident stem cells with an integrating vector becomes feasible. The key question in the context of non-viral vectors is that of efficacy and the repeat dose-trial currently prepared for by the UK CF Gene Therapy Consortium using clinically relevant surrogate end points should address this key question.
